Fortrea Holdings (FTRE) Stock Overview
A contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
FTRE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Fortrea Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.25 |
| 52 Week High | US$25.28 |
| 52 Week Low | US$3.97 |
| Beta | 1.85 |
| 1 Month Change | 11.06% |
| 3 Month Change | 70.97% |
| 1 Year Change | -52.13% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.62% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Fortrea Holdings (NASDAQ:FTRE) Use Debt?
Aug 14
Fortrea Holdings: What Is There To Like About This Situation
Aug 08Why Fortrea Holdings Inc. (NASDAQ:FTRE) Could Be Worth Watching
Jun 21
New Therapeutic Areas And AI Adoption Will Fuel Progress
Expanding into therapeutic areas and strengthening partnerships may increase revenue through diversified client engagement.Is There An Opportunity With Fortrea Holdings Inc.'s (NASDAQ:FTRE) 49% Undervaluation?
May 08Is Fortrea Holdings (NASDAQ:FTRE) Using Debt Sensibly?
Apr 08Fortrea: A Growing CRO With Strong Backlog, Margin Expansion, And Industry Tailwinds
Mar 06Benign Growth For Fortrea Holdings Inc. (NASDAQ:FTRE) Underpins Stock's 38% Plummet
Mar 04We Think Fortrea Holdings (NASDAQ:FTRE) Has A Fair Chunk Of Debt
Dec 27Fortrea: Turning Around As The Activists Move In
Dec 26Fortrea: Some Green Shoots After A Dismal Period
Nov 28There Is A Reason Fortrea Holdings Inc.'s (NASDAQ:FTRE) Price Is Undemanding
Nov 21Would Fortrea Holdings (NASDAQ:FTRE) Be Better Off With Less Debt?
Aug 16Fortrea Holdings: Still Many Question Marks On This CRO Play
May 12Fortrea: High Risk And Low Upside Potential
Feb 13Fortrea Holdings Inc.'s (NASDAQ:FTRE) Low P/S No Reason For Excitement
Feb 08Fortrea Holdings' (NASDAQ:FTRE) Soft Earnings Are Actually Better Than They Appear
Nov 23Shareholder Returns
| FTRE | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 7.6% | -1.9% | -2.0% |
| 1Y | -52.1% | -6.9% | 12.1% |
Return vs Industry: FTRE underperformed the US Life Sciences industry which returned -7.3% over the past year.
Return vs Market: FTRE underperformed the US Market which returned 12.3% over the past year.
Price Volatility
| FTRE volatility | |
|---|---|
| FTRE Average Weekly Movement | 13.1% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FTRE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: FTRE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2023 | 14,500 | Anshul Thakral | www.fortrea.com |
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures.
Fortrea Holdings Inc. Fundamentals Summary
| FTRE fundamental statistics | |
|---|---|
| Market cap | US$1.02b |
| Earnings (TTM) | -US$1.03b |
| Revenue (TTM) | US$2.76b |
Is FTRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FTRE income statement (TTM) | |
|---|---|
| Revenue | US$2.76b |
| Cost of Revenue | US$2.25b |
| Gross Profit | US$513.60m |
| Other Expenses | US$1.54b |
| Earnings | -US$1.03b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.12 |
| Gross Margin | 18.61% |
| Net Profit Margin | -37.23% |
| Debt/Equity Ratio | 194.2% |
How did FTRE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/07 04:52 |
| End of Day Share Price | 2025/11/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fortrea Holdings Inc. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |